Abivax To Present Seven Scientific Abstracts On Obefazimod, Lead Drug Candidate For Treatment Of Active Ulcerative Colitis At UEG Week 2026 Meeting
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis,
Abivax will show research results about its ulcerative colitis medicine. When a company shares good science data, it shows progress on their most important drug.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.